GCIA
HZNP

Gabelli & Co Investment Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-351,075
Closed -$40.6M – 311
2023
Q3 		$40.6M Buy
351,075
+22,600
+7% +$2.43M 6.61% 2
2023
Q2 		$33.8M Buy
328,475
+22,875
+7% +$2.41M 5.65% 1
2023
Q1 		$33.4M Buy
305,600
+157,900
+107% +$17.5M 6.4% 1
2022
Q4 		$16.8M Buy
+147,700
New +$12.3M 3.58% 6

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Gabelli & Co Investment Advisers's HZNP Position: Q4 2023 in Review

Gabelli & Co Investment Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 351,075 shares — an estimated $40.6M sold.

Gabelli & Co Investment Advisers first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $40.6M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Gabelli & Co Investment Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 351,075 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $40.6M.
  • Gabelli & Co Investment Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Gabelli & Co Investment Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $40.6M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2023, filed 13 Feb 2024.